JP Morgan Maintains Overweight on Arrowhead Pharma, Raises Price Target to $95
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $88 to $95.
JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $88 to $95.